Dexmedetomidine + Lorazepam 2 MG/ML
ApprovedUNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia Agitation
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Trial Timeline
Jul 1, 2023 → Jul 1, 2024
NCT ID
NCT06093451About Dexmedetomidine + Lorazepam 2 MG/ML
Dexmedetomidine + Lorazepam 2 MG/ML is a approved stage product being developed by BioXcel Therapeutics for Schizophrenia Agitation. The current trial status is unknown. This product is registered under clinical trial identifier NCT06093451. Target conditions include Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06093451 | Approved | UNKNOWN |
Competing Products
20 competing products in Schizophrenia Agitation